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Rhinosinusal polyps physiopathology is not fully 
understand, despite numerous hypotheses regarding its 
inflammatory process. Aims: a prospective study regarding 
the gene expression of proteins: anexin-1 and galectin-1, 
which has an anti-inflammatory action and is modulated 
by steroids. Materials and Methods: eleven patients with 
rhinosinusal polyps suffered a biopsy of their polyps at two 
moments: in the absence of systemic steroids and during 
its use. In the two samples we assessed the expression of 
these genes and compared it to the normal nasal mucosa 
in the middle meatus. Results: We noticed that the mean 
expression of the genes which code anexin-1 and galectin-1 
was predominantly increased, regardless of the use of steroids 
in relation to the control nasal mucosa. Notwithstanding, in 
polyps without the use of steroids, the mean gene expression 
of anexin-1 was significantly higher than in the polyps 
which were under the use of steroids. Regarding galectin-1, 
there was no significant difference between the expression 
mean values before and after the use of systemic steroids. 
Conclusion: The genes present an expression increase in the 
polyp mucosa, regardless of the use of steroids; nonetheless, 
the relationship of these two genes of anti-inflammatory 
proteins with steroids did not happen the same way.
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INTRODUCTION
Nasal polyps may be characterized by edema of the 
nasal mucosa associated with degeneration of variable in-
tensity. It generally begins on the middle meatus bilaterally, 
and may extend to the paranasal sinuses and nasal fossae, 
probably associated with various clinical etiopathogenic 
entities.1 Recently, nasal polyps as a condition was clas-
sified in the chronic rhinosinusitis subgroup, where the 
common symptoms are nasal congestion and nasal block, 
facial pain, anterior or posterior discharge, and decreased 
olfaction; nasal polyps, however, may be differentiated 
by the presence of bilateral polypoid degeneration in the 
nasal meatuses.2
Lack of a clear definition is due to poor understan-
ding of the etiopathogeny of this condition. It is clear that 
tissue inflammation with eosinophilia is the main feature 
of inflammatory and edematous polyps, which comprise 
about 90% of nasal polyps. However, the mediators of 
inflammation in this situation are not a conventional in-
flammatory process; eosinophilic inflammation becomes 
persistent and unrelated to known mechanisms of atopy. 
A multifactor cause has been suggested, in which there 
is a resulting variable degeneration of the nasal mucosa, 
which results in nasal block, loss of olfaction, and recur-
ring rhinosinusitis.3
Animal models have shown that anti-inflammatory 
proteins, such as annexin-1 and galectin-1, are involved 
in inflammation. They appear to mediate inflammation 
when glucocorticoids are administered.4-6
Annexin-1 is a family of 12 protein found in mam-
mals; these proteins are able to bind to phospholipids 
and calcium. They are frequent in mammal tissues, with 
a discreet distribution in certain epithelial cells, such as 
those of the respiratory and urinary systems, the skin, the 
synovial, macrophages and tissue leukocytes.7 Annexin-1 
has been implied in several intracellular processes, such 
as intracellular signal transduction, cytoskeleton mem-
brane binding, proliferation and differentiation. Its anti-
inflammatory function is attributed to its ability to inhibit 
phospholipase A2 and to bind to specific granulocyte 
and macrophage surface receptors, inhibiting leukocyte 
diapedesis.7
It has also been demonstrated that glucocorticoids 
may induce annexin-1 synthesis in monocytes and neu-
trophils, but not in other cell lineages; in these, glucocor-
ticoid-induced annexin-1 expression is related with cell 
growth and differentiation.
Galectins are a specific family of lecithins that bind 
to galactosides. Galectin-1 was the first to be described; 
it consists of a homodimeric protein, expressed mainly in 
lymphoid organs such as the thymus, lymph nodes, acti-
vated macrophages and T cells. This suggests an important 
relation with the generation and maintenance immune 
tolerance. Its exact in vivo function remains uncertain be-
cause of rupture of the galectin-1 gene; however, studies 
with galectin-1 inhibitors in rats have shown inhibition of 
acute inflammation, probably by a decreased inflow of 
polymorphonuclear cells.8
Immunohistochemical studies involving compari-
sons between the nasal mucosa of the lower and middle 
nasal turbinates and nasal polyps and between allergic 
and non-allergic subjects have shown variable galectin 
expression in the nasal mucosa. Galectin-1 is expressed 
more in polyps compared to the middle and lower turbi-
nates; however, a higher expression of galectin-1 has been 
found in the lower nasal turbinate compared to the middle 
turbinate. Allergic patients also express more galectin-1, 
although this difference appears not to be significant.9 Such 
variability raises questions about the possible involvement 
of galectin-1 in inflammation in nasal polyps. Some au-
thors have questioned whether increased expression of 
galectin-1 in the lower turbinate, compared to the middle 
turbinate, would be an anti-inflammatory protective effect 
with subsequent inhibition of polyp growth; this could 
explain the absence of polypoid degeneration in the lower 
turbinate. Increased expression in polyps may be an un-
controlled attempt to block pre-installed inflammation. We 
therefore decided to investigate the expression of genes 
that code these two anti-inflammatory proteins (annexin-1 
and galectin-1) in nasal polyps and their response when 
systemic glucocorticoids are given.
PATIENTS AND METHODS
Nasal polyp specimens were taken from patients 
with nasal polyps seen at the otorhinolaryngology outpa-
tient unit of the otorhinolaryngology and head & neck 
surgery department of the São José do Rio Preto medical 
school (FAMERP) in Sao Paulo. These patients agreed to 
participate and signed a free informed consent form that 
had been approved by the Institutional Review Board 
of the abovementioned institution (process number nº 
0220/2001).
This study initially had 15 participants with nasal 
polyps diagnosed by using nasofibroscopy confirmed at 
the pathology lab. These patients were also aged over 18 
years, and had been referred to surgery because clinical 
treatment had failed or because complaints of nasal block 
and anosmia persisted.
Two samples were taken from each of these 15 
patients to form two groups of samples. The first group 
consisted of biopsy samples taken at the first visit, at 
which point patients were not using systemic, topical or 
inhaled corticosteroids and/or anti-histaminic drugs; this 
was group B-1. The second group (B-2) consisted of the 
biopsies taken during surgery; patients had also been given 
systemic corticosteroids - a 1 ml ampoule of betamethasone 
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acetate / betamethasone sodium phosphate administered 
intramuscularly five days before the procedure. The inter-
val between the first and second biopsies varied depen-
ding on when the surgery was scheduled; patients were 
always given corticosteroids before undergoing surgery. 
Continuous medication for elevated blood pressure or for 
controlling blood glucose levels was maintained to avoid 
negative effects on health.
A control group comprised 10 nasal biopsies of the 
nasal mucosa of the middle meatus of recent cadavers, 
obtained from the medical examiner’s office of the FA-
MERP; these were patients that died for other reasons, and 
that had no history of rhinosinusitis or other complaints 
pertaining to the nose.
All biopsies - taken at the outpatient unit on the first 
visit (B1), obtained in the surgical theater during surgery 
(B2), and removed from the nasal mucosa of cadavers 
(controls) - were promptly placed in a liquid nitrogen 
tank and then sent to the laboratory for processing to 
extract RNA with the purpose of verifying the expression 
of genes coding for the proteins annexin-1 and galectin-1 
(RT-QPCR method).10 
Four patients were taken out of the study sample 
during RNA extraction, because their sample RNA had 
degraded. In the end, there were 11 patients with two 
paired samples, one of patients not using corticosteroids 
and another of patients using corticosteroids.
The reagent Trizol® (Invitrogen®) was used for 
extracting RNA. The next step was to establish the concen-
tration of RNA, which was done according to wavelength: 
DO260/ DO280. Agarose gel electrophoresis (1%) was 
done of one 1μg of each sample to verify the presence or 
absence of degraded RNA. Analysis of the gel with ultra-
violet light would show an RNA track, with specific 28S 
and 18S bands representing ribosomal RNA.
From the total extracted RNA, cDNA was obtained 
by using the cDNA high capacity kit (Applied Biosystems), 
where 1.25μL anchored oligo (dT) (500μg/mL) and 2μL 
RNAse Out (40U/μL) are added. The cDNA quality was 
assessed by PCR amplification of a 613pb fragment of the 
gene b-ACTIN, which is used as a control for abundant 
transcripts. The sequences of oligonucleotide bases used 
for amplifying the fragment were: F 5’ GGCATCGTGA-
TGGACTCCG 3’ and R 5’GCTGGAAGGTGGACAGCG 3’.
Real time quantitative PCR reactions were carried 
out in the ABI Prism® 7300 real time PCR equipment 
(Applied Biosystems). Control samples were pooled to 
minimize variations, since these were samples from di-
fferent patients.
Sample cDNA was tested three times using the Sy-
berGreen PCR Core Reagent Power Kit (Applied Biosyste-
ms). Initiator oligonucleotides for the ANX1 gene were: F 
5’ AGAAGATGTATGGTATCTCCCTTTGC 3’ and R 5’ GAG-
CCACCAGGATTTTCTCATAA 3’. Initiator oligonucleotides 
for the GAL1 gene were: F 5’ CAGCGGGAGGCTGTCTTTC 
3’ and R 5’ CCTGGTCGAAGGTGATGCA 3’. The beta-
tubulin gene was used as the endogenous control of the 
reaction. The oligonucleotide sequence for the beta-tubulin 
gene was: F 5’ TCAACACCTTCTTCAGTGAAACG 3’ and 
R 5’ AGTGCCAGTGCGAACTTCATC 3’. The value of the 
relative expression for the genes Annexin 1 and Galectin 
1 were calculated based on Pfaffl’s work.10 
RESULTS
There were 11 patients whose extracted RNA was 
of good quality enough to meet the research criteria of 
this study, of which 8 (72.7%) were male and 3 (27.2%) 
were female; their age ranged from 35 to 72 years (mean 
- 53.9 years).
Asthma was present in one subject only (9.0%). 
Aspirin intolerance was found in two subjects (18.1%). 
Three subjects had undergone surgery in the past. One 
subject had systemic arterial hypertension. One subject 
presented diabetes, and one patient had hypothyroidism. 
These results are presented in Table 1.
An R ratio was applied to demonstrate the gene 
expression values of the proteins that were studied here; 
this means the number of times that any specific protein 
in a specific group was expressed more relative to another 
group. The R ratio is achieved by processing the same 
sample three times and calculating the mean of these three 
reactions; the R ratio can thus be defined as the mean 
of gene expression that codes a specific protein in three 
reactions in any given patient. The standard deviation of 
the mean of three reactions is named DCT DEVIATION. 
Values of the expression are in log2 in the charts to stan-
dardize the R values graphically.
An increased gene expression value occurs when 
the ratio between the study group and the control group 
is higher than 2 or 1 when using the log2 expression; 
increased expression is not significant when equal to or 
below this ratio. The same relation applies to negative 
values - for patients in which gene expression decreased.
Thus, in corticosteroid-free polyps, increased 
expression of the protein annexin-1 was observed in 9 
(81.8%) of 11 subjects compared to nasal mucosa controls 
(see Chart A of Fig. 1). The analysis of polyps in subjects 
using corticosteroids, compared to nasal mucosa controls, 
showed that gene expression was increased in 6 (54.5%) 
of 11 subjects (see Chart B of Fig. 1). A comparison be-
tween polyps of subjects using or not using corticosteroids 
showed that only 3 subjects (27.2%) had a significantly 
increased gene expression; however, 7 (63.6%) of 11 
subjects had a significantly decreased protein expression 
(chart C of Fig. 1).
Assessment of the galectin-1 protein comparing 
corticosteroid-free polyps with nasal mucosa controls 
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showed that expression was increased in 9 (81.9%) of 11 
subjects (chart A, Fig. 2). A comparison between polyps of 
patients using corticosteroids with nasal mucosa controls 
showed that expression was increased in 9 (81.9%) of 11 
subjects (chart B of Fig. 2). A comparison between polyps 
of subjects using corticosteroids and corticosteroid-free 
polyps showed that only 3 subjects (27.2%) had a signifi-
cantly increased galectin-1 gene expression. On the other 
hand, a significantly decreased expression of the protein 
galectin-1 was observed in 6 (54.5%) of 11 subjects (chart 
C of Fig. 2).
DISCUSSION
The anti-inflammatory effects of annexin-1 has 
been demonstrated in mice that had their annexin-1 gene 
suppressed.4 We found that when annexin-1 expression 
is suppressed, there is an increase in the expression of 
mRNA for pro-inflammatory cytokines - such as IL-1β, 
TNF-α, IL-6 and MIF - in synovial cells following induction 
of inflammation.
Other studies11,12 have shown that antiannexin-1 
antibodies block glucocorticoid-induced inhibition of 
Table 1. Clinical features of patients in our sample
Patients Age Sex Aspirin intolerance Asthma Previous surgery Associated conditions
01 68 M present - - no
02 72 M - - - Diabetes
03 43 F - - - no
04 49 M present - - no
05 53 F - - present no
07 55 F - - present Hypothyroidism
08 67 M - - -
Systemic arterial 
hypertension
09 35 M - - - no
10 36 M - present - no
11 52 M - - present no
13 63 M - - -
Systemic arterial 
hypertension
Figure 1. Gene expression values in log2 of the anti-inflammatory pro-
tein annexin-1 in nasal polyps. RT-QPCR was used to measure mRNA 
levels of the annexin-1 protein-coding gene in samples of: normal nasal 
mucosa - control group; polyps without corticoids - group B1; and 
polyps with corticoids - group B2. Annexin-1 gene expression in polyp 
tissues without corticoids compared to controls (Chart A); polyps with 
corticoids compared to controls (Chart B); and polyps with corticoids 
compared to polyps without corticoids (Chart C).
Figure 2. Gene expression values in log 2 of the anti-inflammatory pro-
tein galectin-1 in nasal polyps. RT-QPCR was used to measure mRNA 
levels of the annexin-1 protein-coding gene in samples of: normal nasal 
mucosa - control group; polyps without corticoids - group B1; and 
polyps with corticoids - group B2. Galectin-1 gene expression in polyp 
tissues without corticoids compared to controls (Chart A); polyps with 
corticoids compared to controls (Chart B); and polyps with corticoids 
compared to polyps without corticoids (Chart C).
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neutrophil and monocyte recruitment. These antibodies 
also exacerbate inflammation, suggesting an effect of glu-
cocorticoids on inflamed tissues if annexin-1 is also present 
that enhances its anti-inflammatory effect.
On the other hand, immunohistochemical studies 
assessing the occurrence of annexin-1 in the nasal mucosa 
have shown that its expression was altered according to 
cell type, site, and differentiation. There was, however, 
no difference in expression between normal and inflamed 
nasal mucosa, whether in perennial rhinitis or in nasal 
polyps, suggesting that the expression of annexin-1 remai-
ned unaltered in the chronically inflamed nasal mucosa.7
By using the RT-QPCR technique, we found that the 
majority of patients (81.8%) had a significantly increased 
expression of the gene that codes annexin-1, compared 
to the normal nasal mucosa. This finding shows that an-
nexin-1 probably is part of inflammation in nasal polyps, 
since its expression was increased - compared to the 
normal mucosa - regardless of whether the polyps were 
under the influence or not of systemic corticosteroids. The 
mean expression of annexin-1, however, was decreased 
when subjects were using glucocorticoids; this differs 
from animal models in which dexamethasone expression 
increased the expression of the annexin-1 protein.
Annexin-1 increased significantly following admi-
nistration of glucocorticoids in only two of 11 subjects in 
this study. The fact that this increased expression did not 
occur in most subjects appears odd, since annexin is an 
anti-inflammatory protein.  On the other hand, studies of 
MCF-7 cells that were incubated and treated with dexame-
thasone or hydrocortisone did not reveal altered expression 
or cell distribution of annexin.13
The effect of annexin appears to occur in the acute 
phase, during which neutrophils predominate;11 the mu-
cosa of nasal polyps, on the other hand, is in a chronic 
inflammatory state in which eosinophils predominate. The 
presence of polymorphonuclear cells may vary according 
to the intensity of inflammation. This seems pertinent to the 
present study, since the mean expression of annexin-1 was 
higher in group B1 compared to group B2. Inflammation 
was more intense in the first group; although still present, 
inflammation was less intense in the second group because 
subjects had been given glucocorticoids.
An experimental study of rheumatoid arthritis indu-
ced by collagen infiltration6 showed that galectin-1 appears 
to suppress chronic inflammation; injecting fibroblasts 
modified to secrete galectin-1 (or continuous administra-
tion of recombinant galectin) abolished the clinical and 
histopathological manifestation of arthritis.
A study that applied immunohistochemical techni-
ques to evaluate the occurrence of galectin-1 in the nasal 
mucosa found that galectin-1 is expressed more in polyps 
compared with the mucosa of the middle and inferior nasal 
turbinate. However, expression tended to be higher in 
allergic patients and in the lower turbinates, which could 
be interpreted as protection against inflammation and 
inhibition of polyp growth, since polyps do not develop 
in lower turbinates.
In that study, a higher expression of galectin-1 
was also found in polyps, compared to the normal nasal 
mucosa; however, allergic and non-allergic subjects were 
not grouped separately, since the reported incidence of 
allergic patients among those with nasal polyps is similar 
to that of the general population.14
It has been reported that the anti-inflammatory 
effect of glucocorticoids is to increase the transcription of 
anti-inflammatory genes - such as the leukocyte-inhibitor 
protein - and to decrease the transcription of inflammation 
genes,5 such as the macrophage colony stimulating fac-
tor; such mechanisms, however, remain unclear. Another 
study evaluated the relation between galectin-1 and the 
administration of nasal budesonide in patients with nasal 
polyps;15 it showed that budesonide significantly raised ga-
lectin-1 expression in the polyps of allergic patients. These 
results were not seen in non-allergic patients. The study 
also reported that two allergic patients (out of four) also 
presented increased expression of the galectin-1 coding 
gene; expression was decreased in the other two patients, 
although they had a significantly higher gene expression 
compared to normal controls.
This study showed that both annexin-1 and ga-
lectin-1 are raised in most polyps, regardless of whether 
patients are using systemic glucocorticoids or not; we 
found, however, that when glucocorticoids are used, 
there was a significant decrease in the mean expression 
of annexin-1 (in the RT-QPCR method). On the other 
hand, the number of patients with decreased expression 
of proteins remained the same. The mean expression of 
galectin-1 was decreased when glucocorticoids were used, 
but this decrease was not significant, suggesting that the 
relation between these two anti-inflammatory proteins and 
glucocorticoids is dissimilar.
We expected initially that corticoids would raise 
the expression of these anti-inflammatory proteins; we 
found, however, that polyps without corticoids would 
present a highly inflamed state, where these proteins are 
overexpressed, probably to decrease inflammation. When 
glucocorticoids were given, inflammation decreased, which 
consequently lowered expression; nevertheless, expression 
remained high compared to the control nasal mucosa.
CONCLUSION
We concluded that there is an increased expression 
of genes that code the anti-inflammatory proteins anne-
xin-1 and galectin-1 in nasal polyps. When subjects were 
given systemic corticosteroids, the mean gene expression 
of annexin-1 decreased significantly and the mean expres-
sion of galectin-1 remained unaltered.
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